It’s well documented that Johnson & Johnson will split into two companies, a major announcement that was made in November 2021. Since then, the planned entities have been referred to as the new Johnson & Johnson and the New Consumer Health Co. Now, the latter has its own identity.
The New Brunswick-based drugmaker announced Sept. 28 that the new consumer health firm will be called Kenvue. The name comes from the word “ken,” meaning knowledge, and “vue,” referring to sight.
Meaning behind the logo
Johnson & Johnson said the new logo represents Kenvue’s “timelessness, while allowing space for its iconic brands to also have a home.” The “K” embodies the company’s strengths – “the geometry of the rectangle representing scientific precision and the round edges evoking the warmth of care.” The rich green color complements those of the company’s brands.
“Unveiling the Kenvue brand is a defining moment for our stakeholders and an important part of the planned separation,” Thibaut Mongon, CEO designate of Kenvue, said in a statement. Mongon was named to the position in May.
“We believe that daily self-care rituals add up over time and have a profound cumulative impact on your wellbeing. This is the extraordinary power of everyday care. And our work is to put that power into the hands of consumers around the world,” Mongon added.
The company also unveiled its new logo and purpose, to “Realize the Extraordinary Power of Everyday Care,” a belief that will guide its strategies and actions.
“Today’s announcement is another milestone for the Consumer Health business,” said Johnson & Johnson CEO Joaquin Duato. “Kenvue is poised to thrive as a standalone company with a leading portfolio of brands consumers love and trust. I’m confident in this team and excited to see what the future holds.”
Kenvue is still on track to become a standalone company in 2023, subject to legal requirements. Its brands will include Aveeno, Band-Aid, Listerine, Neutrogena, Tylenol, Johnson’s and Dr. Ci:Labo.
In August, the company announced former CVS Health President and CEO Larry Merlo will serve as non-executive chair designate of the future consumer health company.
According to Johnson & Johnson, the Consumer Health segment generated revenue of $14.6 billion in 2021 and, following the planned separation, Kenvue would generate sales in more than 100 countries.